Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows

Reuters11-06

<a href="https://laohu8.com/S/ACRS">Aclaris Therapeutics</a> Q3 revenue beats estimates, net loss narrows

Overview

Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline
Net loss for Q3 smaller than expected, reflecting better financial performance
Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis

Outlook

Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications
Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026
Aclaris expects cash runway to fund operations into H2 2028

Result Drivers

NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024.

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$3.30 mln	$1.59 mln (6 Analysts)
Q3 Net Income	Beat	-$14.61 mln	-$15.80 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 67.7% above its November 5 closing price of $2.26

Press Release: ID:nGNX25vlxp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581218062?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581218062","market":"nz","top_or_hot":-1,"title":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> Q3 revenue beats estimates, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline</p></li><li><p>Net loss for Q3 smaller than expected, reflecting better financial performance</p></li><li><p>Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications</p></li><li><p>Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026</p></li><li><p>Aclaris expects cash runway to fund operations into H2 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024. </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.30 mln</p></td><td><p>$1.59 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$14.61 mln</p></td><td><p>-$15.80 mln (6 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aclaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $7.00, about 67.7% above its November 5 closing price of $2.26</p></li></ul><p>Press Release: <span>ID:nGNX25vlxp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics Q3 revenue beats estimates, net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> Q3 revenue beats estimates, net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline</p></li><li><p>Net loss for Q3 smaller than expected, reflecting better financial performance</p></li><li><p>Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis</p></li></ul><p><span>Outlook</span></p><ul><li><p>Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications</p></li><li><p>Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026</p></li><li><p>Aclaris expects cash runway to fund operations into H2 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024. </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$3.30 mln</p></td><td><p>$1.59 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$14.61 mln</p></td><td><p>-$15.80 mln (6 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aclaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $7.00, about 67.7% above its November 5 closing price of $2.26</p></li></ul><p>Press Release: <span>ID:nGNX25vlxp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACRS","symbol_name":"Aclaris Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0JM:1","article_id":"2581218062","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581218062","pubTimestamp":1762430862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrowsOverviewAclaris Q3 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 smaller than expected, reflecting","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACRS":"Aclaris Therapeutics","BK4007":"制药"},"translate_title":"Aclaris Therapeutics第三季度收入超出预期，净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":0.9},"content_text":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrowsOverviewAclaris Q3 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 smaller than expected, reflecting better financial performanceCompany reports positive Phase 2a trial results for ATI-2138 in atopic dermatitisOutlookAclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indicationsCompany expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026Aclaris expects cash runway to fund operations into H2 2028Result DriversNET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024. Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$3.30 mln$1.59 mln (6 Analysts)Q3 Net IncomeBeat-$14.61 mln-$15.80 mln (6 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 67.7% above its November 5 closing price of $2.26Press Release: ID:nGNX25vlxpFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581218062","isCrawlerRequest":true}